News Conference News TCT 2022 Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year L.A. McKeown September 23, 2022
News Conference News TCT 2022 New Faces, New Formats, New Tech: What to Expect From TCT 2022 Shelley Wood September 07, 2022
News Conference News TVT 2022 Surgical Explant or Redo for TAVI Failures? Some Registry Insights Michael O'Riordan June 10, 2022
News Conference News ACC 2022 ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI Todd Neale April 05, 2022
News Conference News STS 2022 Modified Surgical MV Repair Stands Up to Replacement Michael O'Riordan February 03, 2022
News Conference News EACTS 2021 More Deaths With Bioprosthetic Than Mechanical AVR in Young AS Patients Michael O'Riordan October 18, 2021
News Conference News ACC 2021 Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC Michael O'Riordan May 17, 2021
News Conference News TCT 2020 Acurate Neo Fails to Match Results of CoreValve Evolut: SCOPE 2 Michael O'Riordan October 15, 2020
News Conference News TVT 2020 Device Explants After TAVR Rare but Risky Michael O'Riordan June 24, 2020
News Conference News ACC 2019 Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery Michael O'Riordan March 17, 2019
News Conference News ACC 2019 ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend Shelley Wood March 11, 2019
News Conference News The Structural Heart Disease Summit 2018 High-Quality TAVR: Does a Minimum Volume Requirement Still Make Sense? Michael O'Riordan June 22, 2018
News Conference News The Structural Heart Disease Summit 2018 Nearly 25% of AVR Patients Experience Anxiety or Depression in First Year Michael O'Riordan June 21, 2018
News Conference News ACC 2018 ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins Shelley Wood March 10, 2018
News Conference News CRT 2018 Ticagrelor: Better Platelet Blockade Post-TAVR? Michael O'Riordan March 07, 2018
News Conference News CRT 2018 Early Low-Risk TAVR Data Reassure, but Durability Questions Remain Michael O'Riordan March 05, 2018
News Conference News ESC 2017 Nonagenarians Fare Well After TAVR, Once They Get Beyond 30 Days Michael O'Riordan August 31, 2017
News Conference News ESC 2017 European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts Shelley Wood August 27, 2017
News Conference News TVT 2017 Merits of Minimalist TAVR: Patient Satisfaction and a Better Bottom Line Michael O'Riordan June 20, 2017
News Conference News TVT 2017 Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base Michael O'Riordan June 17, 2017